Smart combination therapy for liver cancer tackles drug resistance


Liver cancer is one of the most common cancer types worldwide and is especially common in China. A collaborative effort between researchers at the Netherlands Cancer Institute, Oncode Institute, and institutes in Shanghai using CRISPR/Cas has led to the discovery that insensitivity to a liver cancer drug can be prevented if it is given in combination with a second drug.

Haojie Jin et al, “EGFR activation limits response of liver cancer to lenvatinib”, Nature, 21 July 2021. 

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.